ReviewAnnals of medicine2024
Eosinophilic inflammation: a key player in COPD pathogenesis and progression.
Review in Annals of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Anti-type 2 monoclonal antibody therapy for eosinophilic COPD beyond triple therapy: a systematic review and meta-analysis with strict eosinophil inclusion criteria.Frontiers in medicine · 2026Pooled it
- Mepolizumab efficacy in chronic obstructive pulmonary disease: insights from longitudinal patterns of blood eosinophil counts and their variability across 3 clinical trials.American journal of respiratory and critical care medicine · 2026Trial
- Short-term longitudinal variation in exhaled nitric oxide fraction predicts future moderate-to-severe exacerbations in COPD patients on triple therapy: a prospective cohort study.ERJ open research · 2026Article
- Airway Response to Dual Bronchodilation and Its Association with Inflammatory Markers in Treatment-Naïve Chronic Obstructive Pulmonary Disease: A Quantitative Computed Tomography Study.Life (Basel, Switzerland) · 2026Article
- Respiratory Biomarkers: An Opportunity for Patient-Centric Microsampling Approach for Treatment Optimization.Clinical and translational science · 2026Review
- Protective Effect of ThaiFood science & nutrition · 2026Article
- Loneliness in Chronic Obstructive Pulmonary Disease: A Multidimensional Determinant of Clinical Outcomes and Disease Management.Journal of clinical medicine · 2026Review
- From Inflammation to Precision Medicine: Mechanistic Insights into Asthma, COPD, and IPF.Biomedicines · 2026Review
- Epithelial cells in chronic obstructive pulmonary disease exacerbations: Targets for lung repair.Pharmacological reviews · 2026Review
- The Efficacy of High-Flow Nasal Cannula (HFNC) Treatment in Patients with Chronic Type II Respiratory Failure Secondary to COPD.Journal of clinical medicine · 2026Article
- Biodistribution and pulmonary toxicity of branched polyethyleneimine in rats following intratracheal and intravenous exposure.Archives of toxicology · 2026Article
- Impact of ambient particulate matter and meteorological factors on COPD risk and its association with blood eosinophilia.BMC pulmonary medicine · 2026Article
- A 90-day safety study of meat from MSTN gene-edited Mongolian cattle in mice.Scientific reports · 2026Article
- Resident eosinophils in patients with chronic obstructive pulmonary disease: a pilot study.Frontiers in medicine · 2026Article
- Accurate Identification and Intervention System Construction of Treatable Traits in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Protocol for a Randomized Controlled Study.International journal of chronic obstructive pulmonary disease · 2026Article
- Association Between Serum MPO-DNA and CCL26 Levels and Poor Prognosis in Children with Multidrug-Resistant Organism-Associated Pneumonia.International journal of general medicine · 2026Article
- Elevated plasma eosinophil-derived neurotoxin is associated with echocardiographic pulmonary vascular involvement in stable COPD.Frontiers in medicine · 2026Article
- Association of Blood Eosinophil Counts with Expiratory Airflow Limitation: A Multi-Ethnicity Observational Study.Journal of inflammation research · 2026Article
- Beyond pathogens: a narrative review of the immunological nexus of damage-associated molecular patterns and inflammasome activation in sterile AECOPD.Frontiers in immunology · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic Obstructive Pulmonary Disease (COPD) remains a significant public health challenge due to its high morbidity and mortality rates. Emerging research has identified eosinophilic inflammation as a crucial factor in the pathogenesis and exacerbation of COPD, warranting a detailed exploration of its underlying mechanisms and therapeutic implications.
objectiveThis review aims to elucidate the role of eosinophils in COPD, focusing on their contribution to airway remodeling, exacerbation frequency, and the inflammatory cascade.
methodsWe conducted a comprehensive literature review of recent studies that discuss the pathophysiological role of eosinophils in COPD and the clinical outcomes associated with modulating eosinophilic activity.
resultsEosinophils contribute to COPD progression by releasing cytotoxic proteins and cytokines that intensify the inflammatory response and airway alterations. Targeting specific eosinophil-related cytokines with monoclonal antibodies or receptor antagonists may potentially reduce eosinophil counts, mitigate exacerbations, and improve patient outcomes.
conclusionUnderstanding eosinophilic involvement in COPD can facilitate the development of precision medicine approaches, offering more tailored and effective treatment options. Future research should continue to focus on the integration of eosinophil biomarkers in clinical practice to enhance therapeutic decisions and management strategies for COPD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.